Support HDYO

HDYO is the only organization who focus solely on supporting young people impacted by HD around the world. Will you help us?

<span class="translation_missing" title="translation missing: en.hdyo.land.loading">Loading</span>
Home Language and Accessibility What is HD? New to HD? Find Resources Research Ask for Help About HDYO News Videos PDF Resources Join Mailing List Kids Teens Young Adults Parents and Family JoHD Friends Professionals DONATE! Privacy Contact Us

An Update from Sage Therapeteutics

June 11, 2024

Huntington's Disease Youth Organization

HDYO has more information about HD available for young people, parents and professionals on our site:


Dear Huntington’s Disease Advocacy Community,

Today, Sage Therapeutics announced topline results from the Phase 2 SURVEYOR Study. SURVEYOR was a small learning study with three objectives: to determine the magnitude of cognitive impairment in participants with HD compared to healthy participants, to evaluate the safety of dalzanemdor in participants with HD, and to better understand the relationship between changes in cognition and changes in function.

The study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo.

The baseline composite score for participants with HD was markedly lower compared to healthy participants, further underscoring the extent of cognitive impairment associated with HD and the significant unmet need for treatment options. We hope these findings will help contribute to a greater understanding and urgency to address cognitive impairment associated with HD.

The secondary safety endpoint showed that dalzanemdor was generally well-tolerated, and there were no new safety signals observed.

For further information, please see the press release. 

Based on these results, Sage is continuing to evaluate the SURVEYOR Study data and will apply relevant learnings to our ongoing work on the dalzanemdor program.

We would like to acknowledge the meaningful contributions of everyone who made this research possible. Sage is immensely grateful for the time and role played by study participants, family members, care partners, and advocates. We look forward to sharing future updates with the Huntington’s disease community as they become available.

Please be in touch if you have any questions. We look forward to our continued conversation.

With gratitude,

Lesley White, MSW, LICSW Director, Pipeline Patient Engagement & Advocacy

Our content is split into different groups. Choose the group that best describes your needs for more information on HD.

Kids Teens Young Adults Parents and Family JoHD Friends Professionals